STENOCARE confirms guidance and reports limited capital requirements ahead of the first TO1-warrant subscription starting on 6 December 2023
STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
Confirmation of 2023 guidance: Last week, STENOCARE completed the largest delivery to the Danish domestic market to date. The delivery is approximately 30% larger than the previous record in Denmark and covers the patient demand for one quarter. STENOCARE thus fulfils its commitment to security of supply and maintains its all-time-high forecast for 2023 and guidance for Q4-23.
Confirmation of 2024 break-even guidance: STENOCARE has built a comprehensive catalogue of initiatives and assets that together are expected to form the basis for the expected continued growth in 2024. These include a) approval and market introduction of the third product in Denmark, b) sales initiatives for progress in the 5 other international markets, c) launch of additional international markets and products, d) launch of on-line clinic in the UK, e) introduction of next-generation products based on patented technology and f) initiation of sales from STENOCARE's own cultivation facility. STENOCARE thus expects the ongoing revenue growth (as announced above and in the Q3-23 report) to continue in 2024 towards the target of 15 mDKK in sales for the full year 2024, corresponding to growth of more than 100% in 2024 and with a consequent expected break-even during 2024.
Limited capital requirements: This positive development means that STENOCARE'S total capital requirement until the expected break-even in 2024 is now estimated at only approx. 3 mDKK. In addition, the debt of approx. 8.5 mDKK, which remains after the successful issue and loan conversion totalling 15 mDKK in the summer of 2023, is due to be refinanced in 2024. This coincides conveniently with the improved operational cash-flows and creditworthiness, that follow from the expected break-even in 2024.
TO1-warrant (from Wednesday, 6 December 2023): STENOCARE sees several sources to cover this limited need. Including proceeds from the exercise of the current TO1 and TO2 warrants (June 2024). Investors who may wish to participate in these warrant exercises are encouraged to seek information at https://stenocare.com/investor-relations/www.stenocare.com. Further information will be sent out in the coming days, and the investor website will have a new menu under "Share Issue" on 6 December.
Thomas Skovlund Schnegelsberg, CEO and co-founder of STENOCARE says: "I am delighted that we are now - after total investments of approximately 100 mDKK since the start in 2018 - close to self-sustaining operations. There are only a few players in the medical cannabis space that have reached this important milestone. Obviously, we have our sights set on the long term and will continue to work towards European market leadership and further growth for the millions of patients who can benefit from treatment with pharma-grade medical cannabis.”
Sign-up for Stenocare news here: https://stenocare.com/subscribe-for-newsletter/ to automatically receive the latest news and information about the company.
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com
About STENOCARE A/S
Stenocare was founded in 2017 with the purpose of supplying prescription-based medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. Stenocare sources its products from a number of carefully selected international high-quality suppliers and operates a unique, indoor state-of-the-art cultivation facility in Denmark, that has multiple levels of redundancy to safeguard quality and uniformity in a pesticide free production process.
www.stenocare.com www.stenocare.dk